ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tirzepatide

Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.

Drug pageTirzepatide: every studyAll 192 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 22, 202272 company-led studies, 19 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only6917 open or runningphase 4since Jun 22, 2022Apr 29, 2016Nov 2026phase 1 · NCT07299084
Florida Academic Centers Research and Education11 open or runningno phasesince Mar 1, 2024Mar 1, 2024none ahead
Hudson Biotechits history only11 open or runningphase 3since Mar 8, 2026Mar 8, 2026Feb 14, 2027phase 3 · NCT07481747
Lexaria Bioscienceits history only10 open or runningphase 1since Oct 16, 2024Oct 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Florida Academic Centers Research and Education only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named tirzepatideINNProposed as its International Nonproprietary Name in WHO's List 119
  2. Mar 1, 2024First study: no phase study in Hidradenitis SuppurativaFirst studyNCT06301256 · 20 planned

TargetBeta

GIPR →GLP1R →read by rule
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
brenipatideEli Lillyphase 319
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

The one study Florida Academic Centers Research and Education leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06301256Hidradenitis Suppurativa–Not yet recruitingMar 11, 202520

How it is read

Names in the registry

  • “Tirzepatide”, 69 entries
  • “Arm 5- Tirzepatide”, 1 entry
  • “Tirzepatide Dose 1”, 1 entry
  • “Tirzepatide Dose 2”, 1 entry
  • “TIRZEPATIDE”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.